Canada markets close in 4 hours 8 minutes

Satellos Bioscience Inc. (MSCL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.4350-0.0050 (-1.14%)
As of 10:23AM EDT. Market open.
Full screen
Previous Close0.4400
Open0.4350
Bid0.4200 x N/A
Ask0.4350 x N/A
Day's Range0.4350 - 0.4350
52 Week Range0.2200 - 1.2000
Volume500
Avg. Volume45,222
Market Cap18.182M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.2100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.70
  • Newsfile

    Satellos Bioscience Announces Upsize of Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures to up to $2.385 Million

    Toronto, Ontario--(Newsfile Corp. - March 22, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, previously announced on March 15, 2023 a proposed non-brokered private placement offering (the "Offering") of 10% unsecured non-convertible debenture units (the "Units") pursuant to which Satell

  • Newsfile

    Satellos Bioscience to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor Summit

    Ryan Mitchell, PhD and Director of Business Development at Satellos to highlight SAT-3153 and Satellos' novel muscle regeneration technology in two forums at this year's MDA Conference and Summit Toronto, Ontario--(Newsfile Corp. - March 17, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging

  • Newsfile

    Satellos Bioscience Announces Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures of up to $2.25 Million

    Toronto, Ontario--(Newsfile Corp. - March 15, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, today announced a proposed non-brokered private placement offering of 10% unsecured non-convertible debenture units (the "Units") pursuant to which Satellos proposes to raise gross proceeds of u